Do you want to read an article? Please log in or register.
Predictors of progression in systemic sclerosis patients with interstitial lung disease
Interstitial Lung Disease
RECOMMENDED
Related content
Interstitial Lung Disease
Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis
Arthritis Rheumatol.
Volkmann ER, Tashkin DP, Kuwana M, Li N, Roth MD, Charles J, Hant FN, Bogatkevich GS, Akter T, Kim G, Goldin J, Khanna D, Clements PJ, Furst DE, Elashoff RM, Silver RM, Assassi S
doi: 10.1002/art.41020.
RECOMMENDED
Interstitial Lung Disease
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Ann Rheum Dis.
Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O, SENSCIS trial investigators
doi: 10.1136/annrheumdis-2020-217331.
CoughInterstitial Lung Disease
Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases
Respirology.
Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ
doi: 10.1111/resp.13084.
RECOMMENDED
Interstitial Lung Disease
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
N Engl J Med.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM, SENSCIS Trial Investigators.
doi: 10.1056/NEJMoa1903076.
RECOMMENDED
Interstitial Lung DiseasePneumonia
[New developments in systemic sclerosis-associated interstitial lung disease]
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Rev Med Suisse
Humair G, Daccord C, Beigelman-Aubry C, Lazor R
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.
doi: 10.1016/S2213-2600(20)30036-9.
RECOMMENDED
Interstitial Lung Disease
Systemic sclerosis-associated interstitial lung disease
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Perelas A, Silver RM, Arrossi AV, Highland KB
doi: 10.1016/S2213-2600(19)30480-1.
RECOMMENDED
Interstitial Lung Disease
The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J
Birring SS, Bushnell DM, Baldwin M, Mueller H, Male N, Rohr KB, Inoue Y
doi: 10.1183/13993003.01790-2021
RECOMMENDED
Interstitial Lung DiseasePneumonia
Predictors of Progression and Mortality in Patients with Prevalent Rheumatoid Arthritis and Interstitial Lung Disease: A Prospective Cohort Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Mena-Vázquez N, Rojas-Gimenez M, Romero-Barco CM, Manrique-Arija S, Francisco E, Aguilar-Hurtado MC, Añón-Oñate I, Pérez-Albaladejo L, Ortega-Castro R, Godoy-Navarrete FJ, Ureña-Garnica I, Velloso-Feijoo ML, Redondo-Rodriguez R, Jimenez-Núñez FG, Panero Lamothe B, Padin-Martín MI, Fernández-Nebro A
doi: 10.3390/jcm10040874